The Inflammatory Lung Microenvironment; a Key Mediator in MSC Licensing
Recent clinical trials of mesenchymal stromal cell (MSC) therapy for various inflammatory conditions have highlighted the significant benefit to patients who respond to MSC administration. Thus, there is strong interest in investigating MSC therapy in acute inflammatory lung conditions, such as acut...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
MDPI AG
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/207e4121b9d74c4aa142f895cdf33e4e |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|